ad26.mos.hiv
Vaccineexperimental
Clinical trial activity
11 trials · 14 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
7
Phase 3
1
Phase 4
0
Earliest trial started Dec 22, 2014 (NCT02315703)
Timeline
Indications
Mechanism of action
- Human immunodeficiency virus type I enhancer-binding protein 1Immunity, active
HIVEP1 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ad26.mos4.hiv
- ad26.mos.hiv
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06205056 | Phase 1 | Jan 31, 2024 | Duke University, Henry M. Jackson Foundation for the Advancement of Military Medicine, Janssen Pharmaceutica NV, Makerere University, National Institute of Allergy and Infectious Diseases (NIAID), United States Army |
| NCT05769569 | Phase 1 | Sep 1, 2023 | Chulalongkorn University, Henry M. Jackson Foundation for the Advancement of Military Medicine, Janssen Pharmaceutica NV, United States Army |
| NCT04983030 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2021 | Harvard University, Janssen Pharmaceutica NV, National Institute of Allergy and Infectious Diseases (NIAID), Orlando Immunology Center, University of Texas at Houston |
| NCT03964415 | Phase 3 | Jun 21, 2019 | Janssen Pharmaceutica NV |
| NCT03307915 | Phase 1 | Mar 5, 2018 | Harvard University, Janssen Pharmaceutica NV, Ragon Institute of MGH, MIT and Harvard, United States Army |
| NCT03060629 | Phase 2 | Nov 1, 2017 | Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT02935686 | Phase 2 | Mar 31, 2017 | Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT02919306 | Phase 1/Phase 2 (Phase 2) | Sep 16, 2016 | Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT02788045 | Phase 2 | Jul 8, 2016 | Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT02685020 | Phase 1 | Mar 28, 2016 | Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT02315703 | Phase 2 | Dec 22, 2014 | Crucell, Harvard University, International AIDS Vaccine Initiative, National Institute of Allergy and Infectious Diseases (NIAID), United States Army |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (14)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Janssen Pharmaceutica NV | For profit | 10 | 2 | 3 | 2016 |
| Johnson and Johnson | For profit | 5 | 5 | 2 | 2016 |
| United States Army | Government | 4 | 1 | 2 | 2014 |
| Harvard University | Academic/Hospital | 3 | 1 | 2 | 2014 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 3 | 0 | 2 | 2014 |
| Henry M. Jackson Foundation for the Advancement of Military Medicine | Academic/Hospital | 2 | 1 | 1 | 2023 |
| Chulalongkorn University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Crucell | For profit | 1 | 1 | 1 | 2014 |
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| International AIDS Vaccine Initiative | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Makerere University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Orlando Immunology Center | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Ragon Institute of MGH, MIT and Harvard | Academic/Hospital | 1 | 0 | 1 | 2018 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2021 |
14 organizations
Page 1 / 1